CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

SIMPLE SUMMARY: The synthetic lethality (SL) clinical success of PARP inhibitors in homologous recombinant deficient tumors has established a new concept for cancer treatment. For decades, efforts have centered on identifying genetic interactions for determining essential tumoral genes, and more rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Castells-Roca, Laia, Tejero, Eudald, Rodríguez-Santiago, Benjamín, Surrallés, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037779/
https://www.ncbi.nlm.nih.gov/pubmed/33808217
http://dx.doi.org/10.3390/cancers13071591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037779/
https://www.ncbi.nlm.nih.gov/pubmed/33808217
http://dx.doi.org/10.3390/cancers13071591

Ejemplares similares